128 related articles for article (PubMed ID: 7654075)
41. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study.
Ernst M; Zametkin AJ; Matochik JA; Jons PH; Cohen RM
J Neurosci; 1998 Aug; 18(15):5901-7. PubMed ID: 9671677
[TBL] [Abstract][Full Text] [Related]
42. Relationship of striatal dopamine synthesis capacity to age and cognition.
Braskie MN; Wilcox CE; Landau SM; O'Neil JP; Baker SL; Madison CM; Kluth JT; Jagust WJ
J Neurosci; 2008 Dec; 28(52):14320-8. PubMed ID: 19109513
[TBL] [Abstract][Full Text] [Related]
43. Striatal glucose metabolism and [18F]fluorodopa uptake in a patient with tumor-induced hemiparkinsonism.
Miyagi Y; Morioka T; Otsuka M; Fukui M
Neurosurgery; 1993 May; 32(5):838-41. PubMed ID: 8492861
[TBL] [Abstract][Full Text] [Related]
44. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles.
Opacka-Juffry J; Brooks DJ
Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438
[TBL] [Abstract][Full Text] [Related]
45. Lower dopamine tone in the striatum is associated with higher body mass index.
Lee Y; Kroemer NB; Oehme L; Beuthien-Baumann B; Goschke T; Smolka MN
Eur Neuropsychopharmacol; 2018 Jun; 28(6):719-731. PubMed ID: 29705023
[TBL] [Abstract][Full Text] [Related]
46. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
47. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
Melamed E; Hefti F; Wurtman RJ
Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
[TBL] [Abstract][Full Text] [Related]
48. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
Pal PK; Leung J; Hedrich K; Samii A; Lieberman A; Nausieda PA; Calne DB; Breakefield XO; Klein C; Stoessl AJ
Mov Disord; 2002 Jul; 17(4):789-94. PubMed ID: 12210877
[TBL] [Abstract][Full Text] [Related]
49. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.
Pate BD; Kawamata T; Yamada T; McGeer EG; Hewitt KA; Snow BJ; Ruth TJ; Calne DB
Ann Neurol; 1993 Sep; 34(3):331-8. PubMed ID: 8363350
[TBL] [Abstract][Full Text] [Related]
50. Striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography.
Remy P; Hosseini H; Degos JD; Samson Y; Agid Y; Warter JM; Vidailhet M
Ann Neurol; 1995 Dec; 38(6):954-6. PubMed ID: 8526470
[TBL] [Abstract][Full Text] [Related]
51. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
[TBL] [Abstract][Full Text] [Related]
52. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.
Egerton A; Demjaha A; McGuire P; Mehta MA; Howes OD
Neuroimage; 2010 Apr; 50(2):524-531. PubMed ID: 20034580
[TBL] [Abstract][Full Text] [Related]
53. Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
Chiueh CC; Firnau G; Burns RS; Nahmias C; Chirakal R; Kopin IJ; Garnett ES
Adv Neurol; 1987; 45():167-9. PubMed ID: 3103385
[No Abstract] [Full Text] [Related]
54. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Cordes M; Poewe W
Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
[TBL] [Abstract][Full Text] [Related]
55. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT.
van Dyck CH; Seibyl JP; Malison RT; Laruelle M; Wallace E; Zoghbi SS; Zea-Ponce Y; Baldwin RM; Charney DS; Hoffer PB
J Nucl Med; 1995 Jul; 36(7):1175-81. PubMed ID: 7790941
[TBL] [Abstract][Full Text] [Related]
56. Striatal [18F]dopa uptake in familial idiopathic dystonia.
Playford ED; Fletcher NA; Sawle GV; Marsden CD; Brooks DJ
Brain; 1993 Oct; 116 ( Pt 5)():1191-9. PubMed ID: 8221055
[TBL] [Abstract][Full Text] [Related]
57. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits.
Holthoff VA; Vieregge P; Kessler J; Pietrzyk U; Herholz K; Bönner J; Wagner R; Wienhard K; Pawlik G; Heiss WD
Ann Neurol; 1994 Aug; 36(2):176-82. PubMed ID: 8053653
[TBL] [Abstract][Full Text] [Related]
58. Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo.
Dejesus OT; Endres CJ; Shelton SE; Nickles RJ; Holden JE
Synapse; 2001 Jan; 39(1):58-63. PubMed ID: 11071710
[TBL] [Abstract][Full Text] [Related]
59. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration.
Capuron L; Pagnoni G; Drake DF; Woolwine BJ; Spivey JR; Crowe RJ; Votaw JR; Goodman MM; Miller AH
Arch Gen Psychiatry; 2012 Oct; 69(10):1044-53. PubMed ID: 23026954
[TBL] [Abstract][Full Text] [Related]
60. On the use of [18F]DOPA as an imaging biomarker for transplanted islet mass.
Eriksson O; Mintz A; Liu C; Yu M; Naji A; Alavi A
Ann Nucl Med; 2014 Jan; 28(1):47-52. PubMed ID: 24166476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
